ICON Public Limited Company

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2023-12-08 pm EST			5-day change	1st Jan Change
272.46 ^USD	+1.59%		+1.15%	+40.26%

Dec. 04	Let's party like it's 2021
Dec. 04	ANALYST RECOMMENDATIONS : Adobe, Broadcom, Comcast, Fair Isaac, Salesforce...

Presentation Operator MessageOperator (Operator)Hello, and welcome to the ICON plc Q2 2023 Results Conference Call...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about ICON Public Limited Company

Let's party like it's 2021	Dec. 04
ANALYST RECOMMENDATIONS : Adobe, Broadcom, Comcast, Fair Isaac, Salesforce...	Dec. 04
Deutsche Bank Raises ICON Price Target to $320 From $295, Maintains Buy Rating	Nov. 30	MT
Data keeps fueling the momentum	Nov. 30
ANALYST RECOMMENDATIONS : Blackrock, Costco, Dollar Tree, Duke Energy, Snowflake...	Nov. 30
Transcript : ICON Public Limited Company Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 12:30 PM	Nov. 29	CI
Transcript : ICON Public Limited Company Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-14-2023 02:00 PM	Nov. 14	CI
All good things must come to an end	Nov. 07
ANALYST RECOMMENDATIONS : Best Buy, Diageo, Eli Lilly, Estee Lauder, Home Depot...	Nov. 07
ICON Seeks Acquisitions	Oct. 26	CI
Transcript : ICON Public Limited Company, Q3 2023 Earnings Call, Oct 26, 2023	Oct. 26	CI
ICON Q3 Adjusted EPS, Revenue Rise; Full-Year Guidance Disclosed	Oct. 25	MT
Earnings Flash (ICLR) ICON Posts Q3 EPS $3.30, vs. Street Est of $3.28	Oct. 25	MT
Earnings Flash (ICLR) ICON Posts Q3 Revenue $2.06B, vs. Street Est of $2.06B	Oct. 25	MT
Icon Public Limited Company Re-Affirms Earnings Guidance for the Full-Year 2023	Oct. 25	CI
ICON Public Limited Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Oct. 25	CI
ICON Public Limited Company acquired Philips Pharma Solutions.	Oct. 24	CI
Deutsche Bank Adjusts ICON Price Target to $295 From $300, Maintains Buy Rating	Oct. 18	MT
Baird Adjusts Price Target on ICON to $287 From $278, Keeps Outperform Rating	Oct. 17	MT
ICON plc Releases Expanded End-To-End Clinical Trial Tokenisation Solution	Sep. 20	CI
ICON Partners With US Government for Clinical Trial of Next-Generation COVID-19 Vaccine Candidates	Sep. 13	MT
ICON to partner with US govt agency to test COVID vaccine candidates	Sep. 13	RE
ICON to partner with US govt agency to test COVID-19 vaccine candidates	Sep. 13	RE
ICON plc Partners with the U.S. Biomedical Advanced Research and Development Authority to Execute Next Generation COVID-19 Vaccines Clinical Trial	Sep. 13	CI
UBS Adjusts ICON Price Target to $295 From $285, Maintains Buy Rating	Jul. 28	MT

Chart ICON Public Limited Company

Duration

Period

More charts

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors. Its sectors include Biosimilars, Biotech, Government and public health solutions, medical devices, pharmaceuticals and the IVDR journey.

Sector

Biotechnology & Medical Research

Calendar

2024-02-20 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ICON Public Limited Company

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

272.46USD

Average target price

286.21USD

Spread / Average Target

+5.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ICON PUBLIC LIMITED COMPANY	+40.26%	22 431 M $
SEAGEN INC.	+70.40%	41 313 M $
IQVIA HOLDINGS INC.	+5.07%	39 289 M $
MODERNA, INC.	-55.28%	30 625 M $
LONZA GROUP AG	-27.34%	27 758 M $
ALNYLAM PHARMACEUTICALS, INC.	-28.45%	21 339 M $
CELLTRION, INC.	+4.49%	17 693 M $
UNITED THERAPEUTICS CORPORATION	-13.10%	11 356 M $
BIO-TECHNE CORPORATION	-17.58%	10 803 M $
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.17%	10 488 M $